The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot.

Alteration of the p53 gene is the most frequent genetic feature of human cancer and leads to overexpression of the altered protein in the tumor cell nucleus. Two diagnostic procedures are currently available to assess p53 mutations: (a) molecular analysis of the gene sequence; and (b) immunohistochemical analysis of p53 protein accumulation. We now report a third approach, serological analysis. Fifteen % of primary breast cancer patients were found to have circulating antibodies to p53 protein by immunoprecipitation or immunoblotting. We have found a close correlation between the presence of such antibodies and bad prognosis such as high histological grade and the absence of hormone receptors. Furthermore, we found that the B-cell response to p53 protein is induced by two immunodominant regions located at the carboxy and amino termini of the protein, outside the central mutational hot spot region. These findings suggest that serological analysis, combined with molecular and histochemical methods, may be suitable for assessing the state of the p53 gene in cancer patients.

[1]  E. Gurney,et al.  Monoclonal antibodies against simian virus 40 T antigens: evidence for distinct sublcasses of large T antigen and for similarities among nonviral T antigens , 1980, Journal of virology.

[2]  T. Soussi,et al.  Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells. , 1993, Bulletin du cancer.

[3]  Thierry Soussi,et al.  TP53 tumor suppressor gene: A model for investigating human mutagenesis , 1992, Genes, chromosomes & cancer.

[4]  C. Midgley,et al.  p53 immunostaining as a marker of malignant disease in diagnostic cytopathology , 1991, The Lancet.

[5]  D. Slamon,et al.  Frequency and structure of p53 rearrangements in human osteosarcoma. , 1990, Cancer research.

[6]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[7]  R. Katakura,et al.  Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products. , 1991, Oncogene.

[8]  D. Pim,et al.  Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer , 1982, International journal of cancer.

[9]  J. Minna,et al.  Occurrence of p53 gene abnormalities in gastric carcinoma tumors and cell lines. , 1991, Journal of the National Cancer Institute.

[10]  L. Strong,et al.  Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. , 1990, Science.

[11]  D. Pim,et al.  Radioimmunoassay of the cellular protein p53 in mouse and human cell lines. , 1982, The EMBO journal.

[12]  T. Soussi,et al.  Evolutionary conservation of the biochemical properties of p53: specific interaction of Xenopus laevis p53 with simian virus 40 large T antigen and mammalian heat shock proteins 70 , 1989, Journal of virology.

[13]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.

[14]  L. Banks,et al.  Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. , 1986, European journal of biochemistry.

[15]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[16]  B. Vogelstein,et al.  Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells: a comparison of the "hot spot" mutant phenotypes. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[17]  H. J. Evans,et al.  Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours. , 1990, Oncogene.

[18]  W. Blattner,et al.  Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome , 1990, Nature.

[19]  J. Marks,et al.  Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[20]  T. Soussi,et al.  Structural aspects of the p53 protein in relation to gene evolution. , 1990, Oncogene.

[21]  G. Gaidano,et al.  p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukemia. , 1991, Proceedings of the National Academy of Sciences of the United States of America.